GSA Capital Partners LLP grew its position in Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) by 4.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 156,300 shares of the biotechnology company’s stock after buying an additional 6,500 shares during the quarter. GSA Capital Partners LLP owned 0.58% of Inotek Pharmaceuticals Corporation worth $297,000 as of its most recent filing with the Securities and Exchange Commission.
Separately, Goldman Sachs Group Inc. grew its stake in shares of Inotek Pharmaceuticals Corporation by 276.0% in the first quarter. Goldman Sachs Group Inc. now owns 58,758 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 43,131 shares in the last quarter. Institutional investors and hedge funds own 29.16% of the company’s stock.
Shares of Inotek Pharmaceuticals Corporation (NASDAQ ITEK) opened at 2.22 on Wednesday. The firm’s market capitalization is $59.96 million. The stock has a 50 day moving average price of $1.65 and a 200-day moving average price of $1.59. Inotek Pharmaceuticals Corporation has a 52 week low of $0.85 and a 52 week high of $8.06.
Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.23. Equities analysts anticipate that Inotek Pharmaceuticals Corporation will post ($1.05) earnings per share for the current year.
A number of equities research analysts have recently weighed in on the company. Zacks Investment Research cut Inotek Pharmaceuticals Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, September 12th. Canaccord Genuity cut Inotek Pharmaceuticals Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, HC Wainwright cut Inotek Pharmaceuticals Corporation from a “buy” rating to a “neutral” rating and set a $2.00 price objective for the company. in a research note on Tuesday, July 11th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Inotek Pharmaceuticals Corporation presently has an average rating of “Hold” and an average target price of $3.80.
Inotek Pharmaceuticals Corporation Company Profile
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.
Receive News & Ratings for Inotek Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotek Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.